Japanese study confirms TetraGraph monitor as a better indicator of appropriate reversal dose of sugammadex and adequate recovery of neuromuscular function than AMG-based TOF-Watch SX

News: Uppsala, on January 27, 2022. Senzime today announces that a Japanese study published in this month's Anesthesia & Analgesia concludes that TetraGraph EMG is a better indicator to decide on adequate reversal dose of sugammadex and recovery of neuromuscular function than conventional monitoring with acceleromyography- (AMG)-based TOF-Watch SX.

The primary aim of the study was to compare the recovery time from neuromuscular block recorded by the 2 monitors during profound and moderate neuromuscular blocks. EMG-based TetraGraph measurements at start and finish were significantly closer to 100% (baseline) than the measurements obtained with the AMG-based TOF-Watch SX. Additionally, the TOF-Watch SX overestimated recovery from neuromuscular block, which may pose patient safety concerns. The findings therefore suggest that TetraGraph is a better indicator for adequate recovery of neuromuscular block compared to the more variable AMG-based device.

Due to its accuracy, the investigators also suggests that a lower dose of sugammadex (or potentially the use of neostigmine) may be an option for antagonism of block when recovery is monitored with the TetraGraph.

The authors conclude that TetraGraph is a better indicator to decide on adequate reversal dose of sugammadex and to confirm adequate recovery of neuromuscular function than conventional monitoring with AMG-based TOF-Watch SX that overestimated the recovery.

Pia Renaudin, CEO of Senzime, says: *"It was a great pleasure to see yet another study with the TetraGraph, this time in Japan, validating TetraGraph's usability and accuracy. Residual neuromuscular blockade is a preventable complication if clinicians use a precise monitor. Minimizing drug usage is beneficial to both patients and hospital expenditures."*

About the journal

ANESTHESIA & ANALGESIA is the official journal of **the International Anesthesia Research Society** and all members receive the journal as a benefit of membership. It provides monthly peer reviewed articles on the latest advances in drugs, preoperative preparation, patient monitoring, pain management, pathophysiology, etc

For further information, please contact:

Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 70-813 34 17, email: **pia.renaudin@senzime.com**

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq Stockholm's main market (ticker SEZI) since June, 30 2021. www.senzime.com

Attachments

Japanese study confirms TetraGraph monitor as a better indicator of appropriate reversal dose of sugammadex and adequate recovery of neuromuscular function than AMG-based TOF-Watch SX